Lab21 acquires molecular diagnostics company Myconostica Ltd
Lab21 Limited has announced that it has acquired Myconostica Ltd. The financial terms of the deal were not disclosed. The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays. Furthermore it will provide manufacturing capabilities for Lab21 from which it will develop and produce its range of new biomarker assays.
There is a major unmet market need for diagnosis of life threatening invasive fungal disease and the Myconostica products are leaders in this market. Current fungal diagnostic tests based on culturing techniques have significant clinical limitations and Myconostica’s molecular diagnostic approach provides more rapid, sensitive and specific information which will improve clinical outcomes. In addition to developing global sales of Myconostica products, Lab21 will also be launching the Myconostica fungal testing services from its new reference laboratory in South Carolina as well as its laboratory in Cambridge, UK.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
